---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007596"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:01:07.868124+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24

## Summary
- GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.
- Adjusted EBITDA of $92.4M, up 5% YoY; non-GAAP adjusted EPS of $1.45.
- Record Belbuca revenue of $50.7M, up 15% YoY; total prescriptions up 4.2%.
- CEO Joe Ciaffoni to step down May 24, 2024; Michael Heffernan named interim CEO.
- Board authorized $35M accelerated share repurchase program; reiterated FY2024 guidance.

## SEC filing metadata
- accession: 0001558370-24-007596
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/coll-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007596
- JSON: https://secwatch.observer/filing/0001558370-24-007596.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007596.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2024 results: revenue $144.9 million, net income $27.7 million, EPS $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted). Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $144.9 million
  - Net income: $27.7 million
  - EPS: $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: under Item 2.02 of this Current Report on Form 8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports First Quarter 2024 Financial Results ​ – Generated Q1’24 Net Revenue of $144.9 Million – ​ – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – ​ – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.